Stockreport

ArQule Presents Results from Ongoing Phase 1 Dose Escalation Study of its Reversible BTK Inhibitor, ARQ 531

ARQULE  (ARQL) 
Last arqule earnings: 10/30 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: investors.arqule.com/investor-relations
PDF BURLINGTON, Mass.--(BUSINESS WIRE)-- ArQule, Inc. (Nasdaq:ARQL) today is presenting preliminary results from the Company’s Phase 1 dose escalation study fo [Read more]